ArticleOphthalmology and therapy2025
Use of an Eyelid Pressure Patch Concomitantly with a Decellularized Dehydrated Amniotic Membrane for Ocular Surface Disease Management.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Retrospective Review of Glueless, Sutureless Pterygium Excision Using Biovance Triple-Layer Decellularized Amniotic Basement Membrane Tissue.Ophthalmology and therapy · 2026Article
- Comparison of Effectiveness of Biovance Single and Triple Layer Decellularized Basement Membranes for Treatment of Ocular Surface Disease: A Retrospective Study.Clinical optometry · 2026Article
- Retrospective Evaluation of Successive BiovanceClinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPersistent corneal epithelial defects (PCEDs) occur when conditions like dry eye disease (DED), neurotrophic keratitis (NK), and limbal stem cell deficiency impair corneal healing, leading to risks of infection, scarring, or perforation. Decellularized, dehydrated pure amniotic membrane basement membrane (AMBM) supports healing by promoting cell adhesion, growth, and inflammation reduction. Eyelid pressure patching helps stabilize the AMBM, protects the cornea, and enhances its therapeutic effects.
methodsThis retrospective study analyzed 144 eyes treated with either a single-layer or three-layer decellularized AMBM combined with a 24-h eyelid pressure patch.
resultsOf the patients included, 90% received a single-layer AMBM and 10% a three-layer AMBM. In the single-layer group, 100% of cases showed complete healing and AMBM dissolution. In the three-layer group, 100% showed corneal staining improvement, but 20-30% of the AMBM remained undissolved. No patients reported experiencing pain, discomfort, or infection.
conclusionsCombining eyelid pressure patching with amniotic membrane treatment is a safe and effective approach for healing persistent corneal epithelial defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.